FMP
Immuneering Corporation
IMRX
NASDAQ
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
2.43 USD
-0.04 (-1.65%)
About
ceo
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://immuneering.comexchange
NASDAQ
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharma...
CIK
0001790340
ISIN
US45254E1073
CUSIP
45254E107
Address
245 Main Street
Phone
617 500 8080
Country
US
Employee
66
IPO Date
Jul 30, 2021
IMRX Financial Summary
CIK
0001790340
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45254E107
ISIN
US45254E1073
Country
US
Price
2.43
Beta
-0.45
Volume Avg.
6.28M
Market Cap
72.06M
Shares
-
52-Week
1.0-8.89
DCF
1.93
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.28
P/B
-
Website
https://immuneering.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IMRX News
It looks like there's no news available.
